Silo Pharma Closes Private Placement of Common Shares and Pre-Funded Warrants
Silo Pharma, Inc. completed a private placement of common shares and pre-funded warrants, raising approximately $815,000 in gross proceeds.
Stocks · News reference
Silo Pharma reported its financial results for the third quarter of 2026, showing zero revenue and a continued operating loss.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Silo Pharma, Inc. completed a private placement of common shares and pre-funded warrants, raising approximately $815,000 in gross proceeds.
Filed: 2026-11-06 AccNo: 0001213900-26-116982 Size: 738 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
-SEC Filing
On October 1, 2026, Silo Pharma, Inc. (the "Company") entered into an asset purchase agreement (the "Agreement") with Norsight Consulting Inc., an Arkansas corporation (the "Seller"). Pursuant to
The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," is also covered by a corresponding patent issued by the Japan Patent Office